STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

  • STATUS
    Recruiting
  • End date
    Oct 31, 2023
  • participants needed
    280
  • sponsor
    National Cancer Institute (NCI)
Send
Updated on 22 October 2022
See if I qualify

Summary

This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Description

PRIMARY OBJECTIVE:

I. To compare recurrence free survival (RFS) and overall survival (OS) as co-primary endpoints across the two arms.

SECONDARY OBJECTIVES:

I. To evaluate adverse events. II. To evaluate distant metastasis free survival (DMFS). III. To evaluate the impact of radiation on clinical outcomes (OS, RFS, DMFS).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy within 14 days of day 1, cycle 1. Patients undergo positron emission tomography (PET)-computed tomography (CT) or CT scan on a 6 month basis through 5 years.

ARM B: Patients receive standard of care observation every 3 months for 1 year, and then every 6 months for 5 years. Patients may also undergo standard of care radiation therapy within 14 days of day 1, cycle 1. Patients undergo PET-CT or CT on a 6 month basis through 5 years.

After completion of study treatment, patients are followed up every 6 months for 5 years.

Details
Condition Pathologic Stage I Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
Treatment radiation therapy, computed tomography, positron emission tomography, Pembrolizumab, biospecimen collection, Best Practice
Clinical Study IdentifierNCT03712605
SponsorNational Cancer Institute (NCI)
Last Modified on22 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status: 0, 1, or 2 (However, those patients with a performance state of 3 because they are wheel chair bound due to congenital or traumatic events more than one year before the diagnosis of Merkel cell carcinoma are eligible)
Patient must be >= 18 years of age
Patient must have a histological confirmation of diagnosis of Merkel cell carcinoma (MCC), pathologic stages (American Joint Committee on Cancer [AJCC] version 8) I-IIIb
Stage I patients with negative sentinel lymph node biopsy are ineligible. Patients who have a positive biopsy or for whom no biopsy was done are eligible
The primary tumor must have grossly negative margins. (Microscopically positive margins are allowed)
Patients with distant metastatic disease (stage IV) are ineligible
Complete nodal dissection is not required for eligibility
Patients with all macroscopic Merkel cell carcinoma (either identified by physical
Cancers of unknown primary that have regional disease only are eligible
exam or imaging) have been completely resected by surgery within 16 weeks
before randomization
All patients must have disease-free status documented by a complete physical examination and conventional imaging studies within 8 weeks prior to randomization
Patient may not have a history of distant metastatic disease
NOTE: Loco-regional recurrent disease is acceptable, as long as this is not metastatic (prior surgery with or without radiation therapy is acceptable)
For patients with initial presentation of Merkel cell carcinoma, patient must have no
White blood count >= 2000/uL (within 4 weeks prior to randomization)
previous systemic therapy or radiation therapy prior to surgery for Merkel
Absolute neutrophil count (ANC) >= 1000/uL (within 4 weeks prior to randomization)
cell carcinoma and cannot have completed adjuvant radiation therapy for Merkel
Platelets >= 75 x 10^3/uL (within 4 weeks prior to randomization)
Hemoglobin >= 8 g/dL (>= 80 g/L; may be transfused) (within 4 weeks prior to randomization)
cell carcinoma more than 6 weeks prior to randomization. Patients actively
undergoing radiation therapy or having completed adjuvant radiation therapy
Creatinine =< 2.0 x institutional upper limit of normal (ULN) (within 4 weeks prior to randomization)
within 6 weeks of randomization are eligible, as long as resection date is
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN (within 4 weeks prior to randomization)
within 16 weeks of randomization. Patients with prior radiation at a non-
Patients who are human immunodeficiency virus (HIV)+ with undetectable HIV viral load are eligible provided they meet all other protocol criteria for participation
Total bilirubin =< 2.0 x institutional ULN, (except patients with Gilbert's syndrome, who must have a total bilirubin less than 3.0 mg/dL) (within 4 weeks prior to randomization)
Radiation Oncology Core (IROC) provider are eligible for the trial. If the
patient has not received radiation, and treatment at a Radiation Oncology Core
Patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are eligible provided viral loads are undetectable. Patients on suppressive therapy are eligible
(IROC) provider is not possible, the patient can start and complete radiation
prior to randomization, with recommendations to follow radiation protocol
guidelines with submission of treatment records

Exclusion Criteria

Patient must not be pregnant or breast-feeding due to the unknown effects of the study drug in this setting. All patients of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy. A patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Patients on Arm A MK-3475 (Pembrolizumab) must not conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of registration, while on study treatment, and continue for 120 days after the last dose of study treatment. For patients on Arm B only receiving radiation therapy, contraception use should be per institutional standard
Patients must not be on active immunosuppression, have a history of life threatening virus, have had other (beside non-melanoma skin cancers, or recent indolent cancers e.g.: resected low grade prostate cancer) invasive cancer diagnoses in the last two years, or have had immunotherapy of any kind within the last 2 years prior to randomization
Patients must not have a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
Operative notes from patient's surgical resection must be accessible
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note